BioAtla Investor Presentation Deck

BA3011: Best Response in Phase 2 Non-Squamous Patients Non-Squamous patients - Phase 2 only 1.8mg/kg Q2W bicatla % Change in Sum of Target Lesions 100 80 60 40 20 -20 -40 -60 -80 -100 PD PD ---Monotherapy ---Combination SD PD EGFR Failure Interim data- Data cut-off of Oct 28, 2022 SD SD SD TmPS range 1% - 100% Average prior lines of therapy = 3 All patients were PD-1 failure with the exception of 1 NSQ patient who failed EGFR treatment PR confidential PR PR PR CR BioAtla| Overview 19

View entire presentation